The purpose of this study is to test therapeutic benefits of take-home LAAM. (1) Do subjects
with take-home LAAM availability show increased clinical responsibility over subjects
without; (2) Do subjects with take-home LAAM attempt diversion when random recall and other
diversion safeguards are used; (3) Does treatment response correlate with background or drug
use variables at intake, discharge, or during treatment?
1-Year study, participant will be randomly assigned to one of two groups: One will have the
opportunity to earn take-home doses by turning in a designated number of clean urines. Two
will not have the opportunity to earn take-home doses. Clinic visits three times per week.
Urine sample given at each visit.
meets DSM-IV criteria for opiate dependence. M/F, 18 years or older. Certified for LAAm
treatment by a physician. Able to understand english. Willing to provide names, addresses,
and numbers of 3 relatives who can aid in patient location for follow-up visits.
Hypertensive to LAAM. Pregnant or nursing women. Female of childbearing potential who
refuses to use an acceptable form of birth control. Clinically significant abnormality in
hematology, blood work, or UA, ETOH and/or sedative/hypnotic dependence according to
DSM-IV criteria. Medical or psychiatric illness which would jeopardize safe study